Literature DB >> 188341

The influence of prostaglandin G2 on platelet ultrastructure and platelet secretion.

J M Gerrard, D Townsend, S Stoddard, C J Witkop, J G White.   

Abstract

Prostaglandin G2 (PGG2) is a labile endoperoxide produced physiologically following exposure of platelets to aggregating agents. We report here studies using isolated PGG2. This agent stimulates a concentration-dependent internal platelet contraction very similar to that produced by the calcium ionophore A23187. EDTA prevented platelet aggregation but did not prevent PGG2-stimulated internal contraction or secretion. In contrast, prostaglandin E1 and dibutyryl cyclic AMP inhich selectively labilizes platelet granules, was added to platelets together with PGG2 there was a superadditive effect on platelet secretion. Thus, granule labilization induced by PMA is a separable phenomenon and complementary to the effect of PGG2 on contraction. The ultimate degree of secretion is dependent on both processes. Studies using additional inhibitors supported the hypothesis that PGG2 activates platelets (either directly or following conversion to thromboxane A2) by transporting calcium from an intracellular store to the cytoplasmic site of the platelet contractile proteins.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 188341      PMCID: PMC2032055     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  29 in total

1.  The influence of aspirin and indomethacin on the platelet contractile wave.

Authors:  J M Gerrard; J G White
Journal:  Am J Pathol       Date:  1976-03       Impact factor: 4.307

2.  Fine structural alterations induced in platelets by adenosine diphosphate.

Authors:  J G White
Journal:  Blood       Date:  1968-05       Impact factor: 22.113

3.  Relationship between chemical structure and platelet-aggregation activity of prostaglandins.

Authors:  J Kloeze
Journal:  Biochim Biophys Acta       Date:  1969-10-28

4.  Some effects of fibrinogen degradation products (FDP) on blood platelets.

Authors:  Z Jerushalmy; M B Zucker
Journal:  Thromb Diath Haemorrh       Date:  1966-05-15

5.  Labile aggregation stimulating substance (LASS): the factor from storage pool deficient platelets correcting defective aggregation and release of aspirin treated normal platelets.

Authors:  J M Gerrard; J G White; G H Rao; W Krivit; C J Witkop
Journal:  Br J Haematol       Date:  1975-04       Impact factor: 6.998

6.  Effects of the lonophore A23187 on blood platelets I. Influence on aggregation and secretion.

Authors:  J G White; G H Rao; J M Gerrard
Journal:  Am J Pathol       Date:  1974-11       Impact factor: 4.307

7.  Cytochemical electron microscopic studies of the action of phorbol myristate acetate on platelets.

Authors:  J G White; R D Estensen
Journal:  Am J Pathol       Date:  1974-03       Impact factor: 4.307

8.  Physiological role of an endoperoxide in human platelets: hemostatic defect due to platelet cyclo-oxygenase deficiency.

Authors:  C Malmsten; M Hamberg; J Svensson; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

9.  Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.

Authors:  M Hamberg; J Svensson; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

10.  Molecular biology of synaptic receptors.

Authors:  E De Robertis
Journal:  Science       Date:  1971-03-12       Impact factor: 47.728

View more
  3 in total

1.  The ultrastructure of defective human platelets.

Authors:  J G White; J M Gerrard
Journal:  Mol Cell Biochem       Date:  1978-11-01       Impact factor: 3.396

2.  The effects of 1-oleoyl-2-acetylglycerol on platelet protein phosphorylation and platelet ultrastructure.

Authors:  L L Friesen; J M Gerrard
Journal:  Am J Pathol       Date:  1985-10       Impact factor: 4.307

3.  Prostaglandins in experimental otitis media.

Authors:  D M Smith; T T Jung; S K Juhn; N T Berlinger; J M Gerrard
Journal:  Arch Otorhinolaryngol       Date:  1979
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.